These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38422896)

  • 1. Current advances in targeted therapy for metastatic colorectal cancer - Clinical translation and future directions.
    Johnson D; Chee CE; Wong W; Lam RCT; Tan IBH; Ma BBY
    Cancer Treat Rev; 2024 Apr; 125():102700. PubMed ID: 38422896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative Hyperselection of Patients With
    Morano F; Corallo S; Lonardi S; Raimondi A; Cremolini C; Rimassa L; Murialdo R; Zaniboni A; Sartore-Bianchi A; Tomasello G; Racca P; Clavarezza M; Adamo V; Perrone F; Gloghini A; Tamborini E; Busico A; Martinetti A; Palermo F; Loupakis F; Milione M; Fucà G; Di Bartolomeo M; de Braud F; Pietrantonio F
    J Clin Oncol; 2019 Nov; 37(33):3099-3110. PubMed ID: 31539295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR
    Elez E; Kopetz S; Tabernero J; Bekaii-Saab T; Taieb J; Yoshino T; Manji G; Fernandez K; Abbattista A; Zhang X; Morris VK
    Future Oncol; 2024 Apr; 20(11):653-663. PubMed ID: 37815847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial.
    Ciardiello D; Martinelli E; Troiani T; Mauri G; Rossini D; Martini G; Napolitano S; Famiglietti V; Del Tufo S; Masi G; Santini D; Avallone A; Pietrantonio F; Lonardi S; Di Maio M; Zampino MG; Fazio N; Bardelli A; Siena S; Cremolini C; Sartore-Bianchi A; Ciardiello F
    JAMA Netw Open; 2024 Apr; 7(4):e245635. PubMed ID: 38592721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [BRAF-V600E testing in metastatic colorectal cancer and new, chemotherapy-free therapy options. German version].
    Hummel M; Hegewisch-Becker S; Neumann J; Vogel A
    Pathologe; 2021 Nov; 42(6):578-590. PubMed ID: 33956173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
    Napolitano S; De Falco V; Martini G; Ciardiello D; Martinelli E; Della Corte CM; Esposito L; Famiglietti V; Di Liello A; Avallone A; Cardone C; De Stefano A; Montesarchio V; Zampino MG; Bordonaro R; Scartozzi M; Santini D; Di Maio M; De Vita F; Altucci L; Marrone F; Ciardiello F; Troiani T
    JAMA Oncol; 2023 Jul; 9(7):966-970. PubMed ID: 37200022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options.
    Hummel M; Hegewisch-Becker S; Neumann JHL; Vogel A
    Pathologe; 2021 Nov; 42(Suppl 1):98-109. PubMed ID: 34259881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Therapy for Colorectal Cancer.
    Sakata S; Larson DW
    Surg Oncol Clin N Am; 2022 Apr; 31(2):255-264. PubMed ID: 35351276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
    Yang L; Zhang W; Fan N; Cao P; Cheng Y; Zhu L; Luo S; Zong H; Bai Y; Zhou J; Deng Y; Ba Y; Liu T; Aili M; Yin X; Gu K; Dai G; Ying J; Shi J; Gao Y; Li W; Yu G; Xie L; Gai W; Wang Y; Meng P; Shi Y
    EBioMedicine; 2024 Feb; 100():104966. PubMed ID: 38217945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.
    Sartore-Bianchi A; Pietrantonio F; Lonardi S; Mussolin B; Rua F; Crisafulli G; Bartolini A; Fenocchio E; Amatu A; Manca P; Bergamo F; Tosi F; Mauri G; Ambrosini M; Daniel F; Torri V; Vanzulli A; Regge D; Cappello G; Marchiò C; Berrino E; Sapino A; Marsoni S; Siena S; Bardelli A
    Nat Med; 2022 Aug; 28(8):1612-1618. PubMed ID: 35915157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
    Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
    Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
    Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
    Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment outcome comparisons of first-line targeted therapy in patients with KRAS wild-type metastatic colorectal cancer: A nationwide database study.
    Liang YH; Chen KH; Shao YY
    Cancer Med; 2023 Jul; 12(14):15176-15186. PubMed ID: 37325970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1
    Mesti T; Rebersek M; Ocvirk J
    Radiol Oncol; 2023 Mar; 57(1):103-110. PubMed ID: 36942906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.
    Moretto R; Cremolini C; Rossini D; Pietrantonio F; Battaglin F; Mennitto A; Bergamo F; Loupakis F; Marmorino F; Berenato R; Marsico VA; Caporale M; Antoniotti C; Masi G; Salvatore L; Borelli B; Fontanini G; Lonardi S; De Braud F; Falcone A
    Oncologist; 2016 Aug; 21(8):988-94. PubMed ID: 27382031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives.
    Martinelli E; Ciardiello D; Martini G; Troiani T; Cardone C; Vitiello PP; Normanno N; Rachiglio AM; Maiello E; Latiano T; De Vita F; Ciardiello F
    Ann Oncol; 2020 Jan; 31(1):30-40. PubMed ID: 31912793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Validation of Plasma-Based Genotyping for
    Aoki Y; Nakamura Y; Denda T; Ohta T; Esaki T; Shiozawa M; Yamaguchi K; Yamazaki K; Sunakawa Y; Kato T; Okano N; Taniguchi H; Sato T; Oki E; Nishina T; Komatsu Y; Matsuhashi N; Goto M; Yasui H; Ohtsubo K; Moriwaki T; Takahashi N; Horita Y; Boku S; Wakabayashi M; Ikeno T; Mitani R; Yuasa M; Yoshino T
    JCO Precis Oncol; 2023 Jun; 7():e2200688. PubMed ID: 37343204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.